MicroRNAs act as regulators in ovarian
tumorigenesis and progression by involving different molecular pathways. Here, we examined the role of miR-135b on growth,
chemotherapy resistance in OVCAR3 and SKOV3
ovarian cancer cells. MTT assay was performed to examine proliferation. Transwell migration and
matrigel invasion assays were used to assess migration and invasion.
Caspase-Glo3/7 assay was carried out to evaluate apoptosis. The dual-
luciferase reporter assay was performed to validate the putative binding site. Meanwhile, the miR-135b levels in human
ovarian cancer tissue were detected by qPCR assay. Overexpression of miR-135b increased growth, and improved migration and invasion in
ovarian cancer cells. Meanwhile, overexpression of miR-135b decreased the
cisplatin treatment sensitivity in OVCAR3 and SKOV3 cells. The
cisplatin-induced apoptosis was decreased by miR-135b. Furthermore, miR-135b could alter epithelial to mesenchymal transition (EMT) associated
proteins expression including
E-cadherin,
N-cadherin, snail and
Vimentin in
ovarian cancer cells. Further study demonstrated aberrant expression of miR-135b regulated PTEN and p-AKT expression in
ovarian cancer cells. The expression level of miR-135b was increased in human
ovarian cancer tissue, compared with normal ovary tissue. MiR-135b involves in
tumorigenesis and progression in
ovarian cancer cells, and might serve as a promising
biomarker to predict
chemotherapy sensitivity and prognosis in
ovarian cancer.